GW Pharmaceuticals, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has submitted an application under the European Mutual Recognition Procedure (MRP) seeking to expand the marketing authorization for Sativex into France for the treatment of spasticity due to Multiple Sclerosis (MS).
Further reading
Leave a Reply
You must be logged in to post a comment.